Publication|Videos|October 16, 2023
How to De-risk the Development of Highly Sensitive Injectables Using High-Performance Pre-fillable Syringe Systems
Author(s)Stevanato Group
Enrico Barichello, Product Manager for the Syringe Platform at Stevanato Group, discusses the risks associated with the interaction between primary packaging and complex novel therapeutics and describes how to prevent or manage concerns utilizing newer, pre-sterilized syringe systems that have more unique characteristics.
LEARN MORE IN THIS VIDEO:
- How Stevanato Group has responded to challenges pertaining to primary packaging of complex highly sensitive injectables
- Concerns with silicone and biopharmaceutical development
- Features of ALBA® technology for high-performance pre-fillable syringe systems
Related Content
Trending on Pharmaceutical Technology
1
European Regulators Prepare the Pharma Industry for Future Changes as Legislation is Formalized
2
Shilpa CDMO to Launch as Dedicated Complex Small-Molecule Contract Development and Manufacturing Brand at CPHI Milan
3
Assessment of Silicone Oil Cleaning on Indirect Surfaces in Aseptic Manufacturing
4
Six-Month eCOA Timelines Signal Need for Earlier Planning
5